Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis c therapy among patients coinfected with hepatitis c and HIV

摘要

Management of HIV is complicated by the presence of hepatitis C (HCV) infection.1 The recent addition of first-generation nonstructural protein 3/4 A (NS3/4A) serine protease inhibitors, such as boceprevir and telaprevir, has significantly enhanced the probability of achieving a sustained virologic response (SVR).2 Recently, simeprevir and sofosbuvir have been incorporated into treatment guidelines,3 but availability and uptake in foreign markets is a long process. Therefore, patients with HIV/HCV infection in developing countries may still rely on treatment with first-generation NS3/4A protease inhibitors.